Sara Elizabeth Siegler Profile picture
Nov 22, 2021 5 tweets 5 min read Read on X
There are some interesting points in the Tecartus sBLA documents. #CARTcells

📌 formulation volume change

📌 BCA did not last past 12 months

📌 IL-6 was the only biomarker identified for both CRS Grade 3 and above AND NT Grade 3 and above

📌 Numerous trial variables
📌 3 of the 29 sites were inspected — including the 2 sites with the most important protocol deviations: Moffitt; Emory; and UChicago

📌 Insufficient MRD assay data for review by CDRH

📌 PROs were not assessed as part of the sBLA
📌 retreatment data from ZUMA-3 were heavily redacted

📌 FDA identified 3 major trial design issues with ZUMA-3

📌 extrapolation to pediatric population was not possible
📌 FDA and Kite disagreed on quite a few fatalities

📌 FDA noted that the data supporting the use of alternative IL-6 inhibitors (e.g., anakinra) are limited
📌 HLH/MAS emerged as a new safety signal in ALL subjects (relative to subjects with MCL)

📌 HLH/MAS treatment is dictated by institutional standards

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Sara Elizabeth Siegler

Sara Elizabeth Siegler Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sesiegler

Apr 24, 2023
My stack of coupons are now apparently worthless, which means that I won’t be shopping at @BedBathBeyond anymore.
Remember what happened when JCPenny hired a guy from Apple and they did away with JCP coupons? They alienated the customer base. BB&B is now taking the same risk, and it just doesn’t make a lot of sense to me. Then again, I haven’t looked at their financials.
Read 5 tweets
Nov 20, 2021
There is nothing wrong with having open and honest conversations about the data. That doesn’t mean I’m an anti-vaxxer. I’ve had both doses, and I recently had my flu shot as well. Please don’t be afraid to discuss strengths and weaknesses of the booster data.
Name calling is for people who can’t come up with good counter arguments but feel the need to opine. Name calling is not science. Debating the data is science.
I’ve been through this already with the lab leak theory, which I found to be a plausible origin in January of 2020. A lot of people tried to shame me on social media, but you don’t conduct an investigation by immediately declaring one plausible option as conspiracy.
Read 5 tweets
Sep 7, 2021
Hey, @PeterDaszak, why did you redact a peer reviewed publication from your biosketch? That’s very odd. documentcloud.org/documents/2105… ImageImageImageImage
This granted @NIHFunding application is about 200 pages shorter than our P01 resubmission, just for perspective.
That bat lady also redacted her biosketch. If these are @NIHFunding projects, they will be in @NIH RePORTER. It’s very odd to see peer reviewed publications and current grants redacted. What are they trying to hide?
Read 6 tweets
Mar 31, 2021
This list price is more than double the ICER valuation on the CAR. I don’t think the European health authorities are going to green light this CAR at this price. I don’t see Europe paying over $200,000/dose since they don’t care about @NIH fees and/or royalties. $BLUE $BMY
This also highlights a much bigger problem with CARs, esp. for solid tumors. It’s a problem we have always prepared for at SES but could hurt our competitors that plan to charge over $400,000/dose. In solid tumors, if the CARs aren’t curative, they have to be really cheap!
The CARs won’t be curative in solid tumors initially — esp. for the first CARs approved for solid tumors — so companies that think they can charge $400,000+/dose are going to be in for a rude awakening. It’s hard to justify that price tag for next gen CARs. #CARTcells
Read 5 tweets
Mar 30, 2021
I am going to add FDA BPCA trial design SME assembly participant to my biosketch. It’s close to being on a working group.
I kept my camera off today as I have wet hair from my shower. I recall Marisa Mayer being criticized for going to a meeting with wet hair, and hence, I kept my camera off. I will ensure I’m camera ready for the next assembly meeting.
Read 4 tweets
Mar 30, 2021
Are you a part of this SME group, @davidcnorrismd?
Trial design and biostats folks, your expertise is needed. DM me for details on how to join this SME group. #biostats #trialdesign #bayesian #ChildhoodCancer
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(